GTX higher on Capesaris trial results

GTX (GTXI) races higher in early trading in front of a presentation on positive results from a Phase 2 clinical trial on the company's prostrate cancer treatment Capesaris.

GTXI +13.8% premarket

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs